Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570600 | 0.91 | KDM4E (0.42) | KDM4ELMNA | |
| SCHEMBL934315 | 0.90 | KDM4E (0.50) | KDM4ELMNA | |
| Ammonia Solution, Strong SCHEMBL3558292 | 0.90 | KDM4E (0.41) | KDM4ELMNA | |
| SCHEMBL6524170 | 0.86 | KDM4E (0.31) | KDM4E | |
| SCHEMBL24307969 | 0.85 | ADRB2 (0.39) | MEN1KMT2A | |
| SCHEMBL8415956 | 0.83 | GAA (0.40) | KDM4EMEN1KMT2AMETAP1 | |
| SCHEMBL8415958 | 0.83 | GAA (0.40) | KDM4EMEN1KMT2AMETAP1 | |
| SCHEMBL25913116 | 0.82 | SIGMAR1 (0.32) | — | |
| SCHEMBL24307975 | 0.82 | HRH3 (0.40) | — | |
| SCHEMBL24307983 | 0.79 | BTK (0.43) | KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4680608-A1 | 2,6-DIHYDRO-7H-PYRAZOLO[3,4-C]PYRIDIN-7-ONE DERIVATIVES AS ANTI-MALARIAL AGENTS | MMV Medicines for Malaria Venture (CH) | 2026-01-21 | — | — | EP | disclosed |
| US-7994168-B2 | Hexahydro-pyrazino[1,2-A]pyrimidine-4,7-dione derivatives substituted with amino acids | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| US-7652007-B2 | Obesity, type II diabetes; such as 6-(4-Chlorobenzyl)-1-(2,4-dichlorobenzenesulfonyl)-8-isopropylhexahydropyrazino[1,2-a]pyrimidine-4,7-dione | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2010-01-26 | — | — | US | disclosed |
| EP-1597259-B1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-04-30 | — | — | EP | disclosed |
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| EP-1799683-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | Sanofi-Aventis Deutschland GmbH (DE) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006024390-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4, 7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-03-09 | — | — | WO | disclosed |
| EP-1597259-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO 1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Sanofi-Aventis Deutschland GmbH (DE) | 2005-11-23 | — | — | EP | disclosed |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2005-04-21 | — | — | US | disclosed |
| WO-2004072077-A1 | NITROGEN-SUBSTITUTED HEXAHYDROPYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSHLAND GMBH (DE) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070197539-A1 | HEXAHYDRO-PYRAZINO[1,2-A]PYRIMIDINE-4,7-DIONE DERIVATIVES SUBSTITUTED WITH AMINO ACIDS | TYMP, DPYD, P2RX7 | KDM4E 3605/4885MEN1 3501/4885KMT2A 3945/4885 |
| US-20050085483-A1 | Nitrogen-substituted hexahydropyrazino[1,2-a]pyrimidine-4,7-dione derivatives, processes for their preparation and their use as medicaments | DPYD, NUDT1, NT5C2 | KDM4E 2782/4885MEN1 1919/4885KMT2A 4297/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.